UB
PTGX icon

UMB Bank’s Protagonist Therapeutics PTGX Stock Holding History

UMB Bank’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$45.7K Buy
373
+20
+6% +$2.09K ﹤0.01% 1372
2026
Q1 		$37.2K Buy
353
+20
+6% +$1.77K ﹤0.01% 1367
2025
Q4 		$29.1K Buy
333
+75
+29% +$6.14K ﹤0.01% 1433
2025
Q3 		$17.1K Buy
258
+59
+30% +$3.35K ﹤0.01% 1493
2025
Q2 		$11K Buy
199
+41
+26% +$1.97K ﹤0.01% 1574
2025
Q1 		$7.64K Sell
158
-5
-3% -$210 ﹤0.01% 1635
2024
Q4 		$6.29K Hold
163
– – ﹤0.01% 1625
2024
Q3 		$7.33K Buy
+163
New +$6.59K ﹤0.01% 1599

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

UMB Bank's PTGX Position: Q2 2026 in Review

UMB Bank increased its Protagonist Therapeutics (PTGX) stake by 5.7% in Q2 2026, buying an estimated $2.09K and bringing the position to 373 shares worth $45.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1372.

UMB Bank first reported a position in PTGX in Q3 2024 and has held it in 8 quarters since. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • UMB Bank held 373 shares of Protagonist Therapeutics worth $45.7K as of Q2 2026.
  • UMB Bank bought 20 Protagonist Therapeutics shares in Q2 2026, an estimated $2.09K.
  • Protagonist Therapeutics made up ﹤0.01% of UMB Bank's portfolio in Q2 2026, its #1372 holding.
  • UMB Bank first reported a position in Protagonist Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on UMB Bank's 13F filing for Q2 2026, filed 13 Aug 2026.